Bruker BioSciences reported a 33 percent increase in life science mass spectrometry sales in the fourth quarter of 2003 as the company returned to profitability, and pledged to make further inroads into clinical and structural proteomics in 2004 during its quarterly earnings conference call this week.

The company posted total revenues of $73.7 million, up 18 percent from the combined revenues of $62.5 million for Bruker Daltonics and Bruker AXS in the fourth quarter of 2002. Daltonics and AXS merged to become Bruker BioSciences in July 2003.